September 14th, 2020. GlycoT Therapeutics has signed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo.The agreement grants Daiichi Sankyo worldwide and nonexclusive rights to intellectual property that GlycoT currently licenses from the University of Maryland, Baltimore and University of Maryland, College Park. The deal includes an undisclosed upfront payment, annual fees, and royalties on sales of GlycoT.The enzymatic glycoengineering technology platform allows scientists to precisely change and modify the sugars on monoclonal antibodies. Daiichi Sankyo plans to use the technology in the development of new drug candidates.
On August 1, 2019, GlycoT was awarded a Phase I SBIR grant (1R43GM134816, $300,000) from NIH to further streamline its proprietary chemoenzymatic transglycosylation approach for antibodies and other glycoproteins. Such streamlines methods, provided in the form of commercial kits, can help general academic and industrial users to perform glycan-remodeling reactions. The streamlined approach can also be applied in scale-up preparation of homogenous glycoproteins with therapeutic potential.
On April 3, 2019, based on the successful accomplishment of all milestones setup in Phase I SBIR grant, GlycoT was awarded a Phase II SBIR grant (2R44GM123823-01A1, $1,259,261) from the NIH to continue and expand the R&D work to establish a robust and scalable process for production of hypersialylated glycoforms of intravenous immunoglobulin (IVIG) with markedly enhanced anti-inflammatory activity.
On March 20, 2018, GlycoT was awarded a Phase I SBIR grant (1R43GM128547-01, $292,383) from NIGMS to develop a 13C-labeled IgG-Fc glycopeptide library using our technology platform, which could be applied as standards for absolute quantification of antibody glycosylation from recombinant antibodies and clinical samples for quality control of biologics manufacturing, and/or for diagnosis and biomarker discovery.
On July 27, 2017, GlycoT was awarded a Phase I SBIR grant (1R43GM123823-01A1, $218,846) from the National Institute of General Medical Sciences (NIGMS) to establish a robust and scalable process for production of hypersialylated glycoforms of intravenous immunoglobulin (IVIG) with markedly enhanced anti-inflammatory activity.